TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20809682

Group type: EXPERIMENTAL
Intervention: Current catheter model (soft cannula) during the initial 1-month period (P1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: New Accu-Chek FlexLink catheter model during the 3-month period (P2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Current catheter model (soft cannula) during P1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: New Accu-Chek FlexLink catheter model during P2
Number of subjects: 45
Study: 17984186

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (30 mg three times per week, for up to 12 weeks)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Chlorambucil (40 mg/m2 every 28 days, for up to 12 months)
Number of subjects: 297
Study: 15918057

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of valsartan (80 mg/day) and perindopril (4 mg/day)
Number of subjects: 31
Study: 11863242

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Interoceptive exposure (IE)
Number of subjects: 69
Study: 9804712

Group type: EXPERIMENTAL
Intervention: Early discharge (discharge two days after surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard management (discharge after removal of drain)
Number of subjects: 100
Study: 7666645

Group type: EXPERIMENTAL
Intervention: Temporal scleral incision
Number of subjects: 162

Group type: COMPARATOR
Intervention: 12-h limbal incision
Number of subjects: 162
Study: 1341206

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 75 mg daily for 6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Almitrine combined with oxygen (8-10 L/min)
Number of subjects: 23
Study: 6605310

Group type: EXPERIMENTAL
Intervention: Tinoridine 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tinoridine 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tinoridine 800 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tinoridine 200 mg (patients with renal disease)
Number of subjects: 6
Study: 30889207

Group type: EXPERIMENTAL
Intervention: Incentive spirometer volume and pressure oriented (IS-vp)
Number of subjects: 12
Study: 29716563

Group type: EXPERIMENTAL
Intervention: Cranberry extract (2 × 18.5 mg PACs per day)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cranberry extract (37 mg PACs per day)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control dose (2 × 1 mg PACs per day)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control dose (2 mg PACs per day)
Number of subjects: 148
Study: 26821189

Group type: EXPERIMENTAL
Intervention: PG201 (600mg, 300mg twice daily)
Number of subjects: 124

Group type: COMPARATOR
Intervention: SKI306X (600mg, 200mg thrice daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PG201
Number of subjects: 124

Group type: COMPARATOR
Intervention: SKI306X
Number of subjects: 124
Study: 23518215

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (MP) at 32 mg/day for seven days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (MP) at 1 mg/kg/day for four days and 0.5 mg/kg/day for three days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (MP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (MP)
Number of subjects: 40
Study: 22217258

Group type: EXPERIMENTAL
Intervention: Gyejibongnyeong-hwan (GJBNH), taken three times per day for two menstrual cycles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo, taken three times per day for two menstrual cycles
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gyejibongnyeong-hwan (GJBNH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19356394

Group type: EXPERIMENTAL
Intervention: Test formulation (XM02) at 5 microg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Test formulation (XM02) at 10 microg/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Reference product (Neupogen) at 5 microg/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Reference product (Neupogen) at 10 microg/kg
Number of subjects: 56
Study: 17439651

Group type: EXPERIMENTAL
Intervention: Knee-specific training for 12 weeks
Number of subjects: 12
Study: 15893007

Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin (Gem/Cis)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (Pac/Carbo)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Vinorelbine/Cisplatin (Vin/Cis)
Number of subjects: 612
Study: 12044859

Group type: EXPERIMENTAL
Intervention: Vinpocetine (20 mg in 500 ml saline)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (500 ml saline)
Number of subjects: 43
Study: 9754168

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 52
Study: 7652726

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of magnesium
Number of subjects: 58186
Study: 2530745

Group type: EXPERIMENTAL
Intervention: Absorbable monofilament polyglyconate (PG) (Maxon*)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Non-absorbable polyamide (PA) (Ethilon*)
Number of subjects: 167
Study: 1190614

Group type: EXPERIMENTAL
Intervention: Atropine sulfate aerosol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isoproterenol hydrochloride aerosol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 18
Study: 29329154

Group type: EXPERIMENTAL
Intervention: Anodic stimulation (a-tDCS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cathodic stimulation (c-tDCS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study: 30779795

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28419462

Group type: EXPERIMENTAL
Intervention: Roflumilast (selective phosphodiesterase 4 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 25978942

Group type: EXPERIMENTAL
Intervention: Mannitol cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control cream (without mannitol)
Number of subjects: 25
Study: 23200117

Group type: EXPERIMENTAL
Intervention: Robotic-assisted treadmill training (RATT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Manually assisted treadmill training (MATT)
Number of subjects: 16
Study: 21751243

Group type: EXPERIMENTAL
Intervention: fMRI lie detection evidence
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Polygraph evidence
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Thermal facial imaging
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control condition (no lie detection evidence)
Number of subjects: 330
Study: 18929592

Group type: EXPERIMENTAL
Intervention: Isolated complex Chinese characters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolated simple Chinese characters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex characters with flankers of different complexity groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complex characters with flankers of the same complexity group
Number of subjects: 0
Study: 16475633

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine with fentanyl (20 microg) at a conventional high dose of 0.07 mg cm(‐1) (group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.25% levobupivacaine with fentanyl (20 microg) and epidural volume extension with 6 mL of saline (group 2)
Number of subjects: 62
Study: 15005765

Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11189545

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (V.A.C.) therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline-moistened gauze
Number of subjects: 10
Study: 9052356

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 16
Study: 9728231

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate via Autohaler
Number of subjects: 181

Group type: COMPARATOR
Intervention: Sodium cromoglycate via metered dose inhaler (MDI)
Number of subjects: 181
Study: 3489445

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg twice a day and dipyridamole 75 mg three times a day
Number of subjects: 442

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 442
Study: 30950493

Group type: EXPERIMENTAL
Intervention: Azithromycin (20/mg/kg single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 30
Study: 30316695

Group type: EXPERIMENTAL
Intervention: Propofol (1–4 mg kg−1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alfaxalone (0.5–2 mg kg−1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both propofol and alfaxalone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 48
Study: 27471317

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine with trimethoprim-sulfamethoxazole
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Day 3 concentrations of lumefantrine
Number of subjects: 105
Study: 23167308

Group type: EXPERIMENTAL
Intervention: MHBA grafted (TG) - buccal plate thickness ≤ 1 mm (TG-a)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CG) - buccal plate thickness ≤ 1 mm (CG-a)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MHBA grafted (TG) - buccal plate thickness > 1 mm (TG-b)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CG) - buccal plate thickness > 1 mm (CG-b)
Number of subjects: 31
Study: 22100577

Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 20735795

Group type: EXPERIMENTAL
Intervention: OFD+EDTA+EMD
Number of subjects: 24

Group type: COMPARATOR
Intervention: OFD+EDTA
Number of subjects: 24
Study: 18844761

Group type: EXPERIMENTAL
Intervention: Combination therapy (valsartan + hydrochlorothiazide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (valsartan alone)
Number of subjects: 0
Study: 16036126

Group type: EXPERIMENTAL
Intervention: Polished with 1,000-grit sandpaper
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Polished with 1,200-grit sandpaper
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Polished with 1,500-grit sandpaper
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Polished with 2,000-grit sandpaper
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Polished with 2,500-grit sandpaper
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group polished with 2,500-grit or 1,200-grit sandpaper and immersed in distilled water
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Specimens immersed in coffee solution
Number of subjects: 36
Study: 11910259

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 150

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 150
Study: 10341330

Group type: EXPERIMENTAL
Intervention: Individual genomic screening for HCV RNA using a semi-automated genomic amplification assay
Number of subjects: 8417

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 8417
Study: 8942455

Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive group therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Social skills training with active drug supplementation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Social skills training with placebo supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive group therapy with active drug supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive group therapy with placebo supplementation
Number of subjects: 80
Study: 1840324

Group type: EXPERIMENTAL
Intervention: Teicoplanin 15 mg/Kg iv
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teicoplanin 20 mg/Kg iv
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teicoplanin 25 mg/Kg iv
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four exponential equation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tri-exponential model
Number of subjects: 0
Study: 7078016

Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 3
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coded commercial artificial tear solution 4
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Function tests (Schirmer test, break‐up time, goblet cell count)
Number of subjects: 17
Study: 30799018

Group type: EXPERIMENTAL
Intervention: Plant-based hemostatic powder (PBHP) placed intraoperatively
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no PBHP)
Number of subjects: 116
Study: 28657703

Group type: EXPERIMENTAL
Intervention: Oral gel
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oral rinse
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mouth spray
Number of subjects: 300

Group type: COMPARATOR
Intervention: Water
Number of subjects: 300
Study: 26534729

Group type: EXPERIMENTAL
Intervention: Tailored practice and patient plans; training sessions for practitioners in medication prescribing and behavioural change; regular patient recall system.
Number of subjects: 903

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 903
Study: 23432339

Group type: EXPERIMENTAL
Intervention: Melatonin administered at 0.1 μg kg(‐1) h(‐1) for 2 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetics of melatonin
Number of subjects: 18
Study: 21450183

Group type: EXPERIMENTAL
Intervention: Oral extended-release oxybutynin 5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19725235

Group type: EXPERIMENTAL
Intervention: Biotene toothpaste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Colgate Active
Number of subjects: 30
Study: 18051826

Group type: EXPERIMENTAL
Intervention: Food challenge (DBPCFC) in children with IgE-related food allergy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Food challenge (DBPCFC) in children without IgE-related food allergy
Number of subjects: 304
Study: 15826410

Group type: EXPERIMENTAL
Intervention: Short-term counselling in general practice
Number of subjects: 181

Group type: COMPARATOR
Intervention: Routine GP treatment (Control)
Number of subjects: 181
Study: 12031995

Group type: EXPERIMENTAL
Intervention: Slow Rewarming (n = 15, mean rewarming speed: 0.22 degrees +/- 0.07 degrees C/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard Rewarming (n = 15, mean rewarming speed: 0.46 degrees +/- 0.09 degrees C/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (nondiabetic patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rewarming rates
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 30
Study: 9871862

Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.5% solution once daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Timolol maleate gel 0.5% once daily
Number of subjects: 43
Study: 8717212

Group type: EXPERIMENTAL
Intervention: rH‐EPO 9,000 IU intravenously daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: rH‐EPO 10,500 IU subcutaneously every third day for a week
Number of subjects: 86

Group type: COMPARATOR
Intervention: rH‐EPO (various doses)
Number of subjects: 86
Study: 2142293

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB), 250 micrograms inhalation solution
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 343728

Group type: EXPERIMENTAL
Intervention: Sulindac (300-400 mg daily)
Number of subjects: 0
Study: 30269430

Group type: EXPERIMENTAL
Intervention: ISBB (Interscalene Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Number of subjects: 62

Group type: COMPARATOR
Intervention: SCBB (Supraclavicular Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Number of subjects: 62
Study: 27941393

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 25969414

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) tablets, 60 mg (treatment A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Powder formulation delivered to the distal small bowel (treatment B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Powder formulation delivered to the ascending colon (treatment C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aqueous suspension delivered to the ascending colon (treatment D)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) tablets, 30 mg (treatment E)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Granulate formulation with fumaric acid 50 mg delivered to the ascending colon (treatment F)
Number of subjects: 18
Study: 23778782

Group type: EXPERIMENTAL
Intervention: Whole Salba seeds (7g, 15g, 24g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ground Salba seeds (7g, 15g, 24g)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control breads (matched for energy and macronutrient profile)
Number of subjects: 13
Study: 21846929

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Phenylephrine group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lidocaine group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Phenylephrine and epinephrine spray group
Number of subjects: 72
Study: 17882140

Group type: EXPERIMENTAL
Intervention: Caffeine (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tyrosine (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Green Tea Extract (500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17825137

Group type: EXPERIMENTAL
Intervention: Oxybutynin extended release
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oxybutynin immediate release
Number of subjects: 72
Study: 15630270

Group type: EXPERIMENTAL
Intervention: Concord grape juice (CGJ) 5.5 ml/kg body weight/day for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calorie-matched placebo drink
Number of subjects: 40
Study: 11758294

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 100
Study: 9203227

Group type: EXPERIMENTAL
Intervention: Cortisol infusion (15 mg hydrocortisone sodium succinate over 120 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 7898091

Group type: EXPERIMENTAL
Intervention: Ambulatory 24-hour blood pressure monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure at home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-measurement
Number of subjects: 0
Study: 3295501

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Number of subjects: 166

Group type: COMPARATOR
Intervention: Moderate-dose methotrexate
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both high-dose and moderate-dose methotrexate
Number of subjects: 166
Study: 31462406

Group type: EXPERIMENTAL
Intervention: Intubation and ventilation prior to umbilical cord clamping (UCC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intubation and ventilation prior to UCC
Number of subjects: 20
Study: 29625852

Group type: EXPERIMENTAL
Intervention: Homeopathic Q‐potencies of opium and E. coca
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 28852828

Group type: COMPARATOR
Intervention: Normoxia (NM; FiO2 0.21)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Severe normobaric hypoxia (HY; FiO2 0.13)
Number of subjects: 9
Study: 26280790

Group type: EXPERIMENTAL
Intervention: 200 IU vitamin D3 fortified mozzarella cheese with pizza
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 28,000 IU vitamin D3 fortified mozzarella cheese with pizza
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-dose group (28,000 IU)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 96
Study: 23053173

Group type: EXPERIMENTAL
Intervention: Lateral or posterior LV lead location
Number of subjects: 797

Group type: COMPARATOR
Intervention: Anterior LV lead location
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Posterior or lateral LV lead location
Number of subjects: 797
Study: 20002361

Group type: COMPARATOR
Intervention: Propofol from Baxter Laboratories mixed with NaCl 0.9%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol from Baxter Laboratories mixed with 2% lidocaine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol from Laboratorios Gray mixed with NaCl 0.9%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol from Laboratorios Gray mixed with 2% lidocaine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol from Baxter Laboratories
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol from Laboratorios Gray
Number of subjects: 22
Study: 17896223

Group type: EXPERIMENTAL
Intervention: Mouse with tactile feedback signal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular computer mouse
Number of subjects: 0
Study: 16647634

Group type: EXPERIMENTAL
Intervention: Misoprostol and calcium
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tibolone and calcium
Number of subjects: 90

Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 90
Study: 12732840

Group type: EXPERIMENTAL
Intervention: Cremophor RH40 (600 mg 3 times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12